geridonin

has antineoplastic activity; structure in first source

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Stomach Neoplasms (Stomach Cancer) 02/01/2017 - "The novel derivative of oridonin, geridonin, inhibited the growth of human gastric cancer cells MGC 803 both in vitro and in vivo mainly via triggering apoptosis depending on elevating intracellular level of ROS." 02/01/2017 - "In gastric cancer MGC 803 cells, geridonin triggered apoptosis through the mitochondrial pathway depending on caspase. " 02/01/2017 - "On oesophageal, gastric cancer cells, geridonin displayed strong cytotoxicity than that of oridonin. " 11/08/2016 - "Thus, geridonin in combination with paclitaxel is a new treatment strategy for gastric cancer." 11/08/2016 - "Geridonin and paclitaxel act synergistically to inhibit the proliferation of gastric cancer cells through ROS-mediated regulation of the PTEN/PI3K/Akt pathway."
2.	Neoplasms (Cancer) 11/08/2016 - "Mechanistic analysis revealed that administration of geridonin in combination with paclitaxel up-regulated the tumor suppressor PTEN and inhibited phosphorylation of Akt and MDM2. "
3.	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 02/01/2017 - "In vitro, geridonin remarkably inhibited proliferation of gastrointestinal cancer cells including oesophageal, gastric, liver and colon cancers. "
4.	Colonic Neoplasms (Colon Cancer) 02/01/2017 - "In vitro, geridonin remarkably inhibited proliferation of gastrointestinal cancer cells including oesophageal, gastric, liver and colon cancers. "